Clinical course of stage IV invasive mucinous adenocarcinoma of the lung

Highlights • Stage IV IMAs have distinct clinicopathological characteristics. • Stage IV IMAs might be less aggressive than stage IV INMAs. • Platinum-based chemotherapy might not be beneficial in IMA patients.

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 102; pp. 82 - 88
Main Authors Cha, Yoon Jin, Kim, Hye Ryun, Lee, Hye-Jeong, Cho, Byoung Chul, Shim, Hyo Sup
Format Journal Article
LanguageEnglish
Published Ireland Elsevier Ireland Ltd 01.12.2016
Subjects
Adenocarcinoma - diagnostic imaging
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adenocarcinoma of Lung
Adenocarcinoma, Mucinous - diagnostic imaging
Adenocarcinoma, Mucinous - drug therapy
Adenocarcinoma, Mucinous - pathology
Aged
Antineoplastic Agents - therapeutic use
Disease-Free Survival
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung cancer
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Mucinous
Mutation
Neoplasm Invasiveness
Neoplasm Staging
Prognosis
Protein Kinase Inhibitors - therapeutic use
Pulmonary/Respiratory
Retrospective Studies
Stage IV
Survival Analysis
Tomography, X-Ray Computed
Treatment Outcome
lung cancer
mucinous
prognosis
treatment outcome
stage IV
Treatment outcome
Mucinous
Prognosis
Stage IV
Lung cancer
Online AccessGet full text

Cover

More Information
Summary:Highlights • Stage IV IMAs have distinct clinicopathological characteristics. • Stage IV IMAs might be less aggressive than stage IV INMAs. • Platinum-based chemotherapy might not be beneficial in IMA patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2016.11.004